Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Sanofi, Asahi Kasei Pharma Tie Up for Anti RA Treatment Kevzara
December 11, 2017
- Janssen Files Guselkumab for Palmoplantar Pustulosis in Japan
December 11, 2017
- Emicizumab Every Four Weeks Delivers Positive Data, Chugai Plans New Dosage Filing Next Year
December 8, 2017
- Avapro AGs Hit Market, Talion AG Won’t Arrive Until March
December 8, 2017
- FDA Clears Sunovion’s Nebulized COPD Drug
December 7, 2017
- Lenvima Filed for HCC in Taiwan: Eisai
December 7, 2017
- Astellas, Univ. of Tokyo, Chiba Univ. Strike Collaborative Research Deal on Rice-Based Oral Vaccine
December 7, 2017
- Positive Update Out for Burosumab in Adult XLH: Kyowa Kirin
December 6, 2017
- GSK Poised to Re-Enter Japan Oncology Space with Novel Myeloma Drug
December 6, 2017
- Astellas Snapping Up US Mitochondrial Disease Specialist Mitobridge
December 5, 2017
- Takeda Officially Organizes “Shonan Health Innovation Park”; Ex-Lilly Japan R&D Chief to Wield the Baton
December 5, 2017
- Daiichi Sankyo Winds Up Deal on Thrombus Dissolving Agent amid Re-Prioritization Drive
December 5, 2017
- ASKA Expands Testosterone Deal with TesoRx Pharma
December 5, 2017
- Pfizer Sues Meiji Seika Pharma, Claiming Infringement of Zyvox Patent
December 5, 2017
- Takeda Spin-Off Chordia Aims to Develop Oncology Blockbuster Drug
December 4, 2017
- Ayumi Looks to Haul in Over 10 Billion Yen from 3 RA Biosimilars: President
December 1, 2017
- Hiroshima Univ. Spinoff Initiates PIII Study for Regenerative Cellular Medicine for Chondrogenesis in Knee
December 1, 2017
- Novartis to Keep Close Eye on Discussions on Clozaril at Chuikyo, Expects Strengthened Measures to Promote Proper Use
November 30, 2017
- Pfizer Lifts Shipment Adjustments of 3 Brands/4 Products after Resuming Operations at Hurricane-Hit Plant in Puerto Rico
November 30, 2017
- Takeda Launches PI Study of Zika Vaccine Candidate
November 30, 2017
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…